Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?

Reviews in Gastroenterological Disorders

Volumn 2, Issue SUPPL. 2, 2002, Pages

  Fennerty, M Brian ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acid suppresion; Antireflux therapy; Barrett's esophagus; COX 2 inhibition; Endoscopic injury; Esophageal cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BICARBONATE; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SULINDAC;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DYSPLASIA; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; EVIDENCE BASED MEDICINE; HEARTBURN; HUMAN; INTESTINE METAPLASIA; MALE; NONHUMAN; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PRECANCER; REVIEW;

ADENOCARCINOMA; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; HEARTBURN; HUMANS; INCIDENCE; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OMEPRAZOLE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RANDOMIZED CONTROLLED TRIALS;

EID: 0036445694     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric cancer in the United States. Cancer. 1998;83:2049-2053.
2. Locke GR, Talley N, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology. 1997;112:1448-1456.
3. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.
4. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med. 1992;326:786-792.
5. Kim SL, Waring JP, Spechler SJ, et al. Effects of anti-reflux therapy on the extent of Barrett's epithelium. Gastroenterology. 1993;104:A118.
6. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA. 2001;285:2331-2338.
7. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286-1293.
8. Sampliner R. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994;89:1844-1848.
9. Sampliner RE, Fennerty MB, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:523-525.
10. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology. 1993;104:1686-1691.
11. Grade AJ, Shah IA, Medlin SM. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest Endosc. 1999;50:18-22.
12. Overholt G, Haggitt R, Bronner M, et al. A multi-center, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porphimer sodium for the ablation of high-grade dysplasia in Barrett's esophagus: results of a 6-month follow-up. Gastroenteroogy. 2001;120:A79.
13. Sharma P, Morales TG, Bhattacharyya A, et al. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol. 1998;93:332-335.
14. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's esophagus. Gut. 2000;46:574-577.
15. Thun MJ, Namboodiri MM, Calle EE. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
16. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal cancer. Cancer. 1995;76:1116-1119.
17. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97-102.
18. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642-1646.
19. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998;58:2929-2934.
20. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487-496.
21. Buttar NS, Anderson MA, Krishnadath KK, et al. Chemopreventive potential of selective cyclooxygenase inhibition in Barrett's epithelium: an in vitro study. Gastroenterology. 2000;118:A35.
22. Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology. 2002;123:60-67.
23. Buttar NS, Wang KK, Leontovic O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 2002;122:1101-1112.
24. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120-2128.
25. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
26. Fennerty MB. Barrett's-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials? Gastroenterology. 2002;122:1171-1174.